Treatment of systemic lupus erythematosus: New advances in targeted therapy

Annals of the New York Academy of Sciences

Volumn 1247, Issue 1, 2012, Pages 138-152

  Lo, Mindy S ^a,b   Tsokos, George C ^b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Belimumab; Biologic; Syk; Systemic lupus erythematosus; Tolerance

Indexed keywords

ABATACEPT; ABETIMUS; AIN 457; AMG 577; AMG 811; ATACICEPT; AZATHIOPRINE; BELATACEPT; BELIMUMAB; BG 9588; BRIOBACEPT; CHLOROQUINE; CYCLOPHOSPHAMIDE; DV 1179; ECULIZUMAB; EDRATIDE; EPRATUZUMAB; FASUDIL; FOSTAMATINIB; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LY 3009104; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RAPAMYCIN; RITUXIMAB; RONTALIZUMAB; TOCILIZUMAB; TORALIZUMAB; UNCLASSIFIED DRUG; USTEKINUMAB; VELTUZUMAB;

ABDOMINAL CRAMP; ARTICLE; B LYMPHOCYTE; BLADDER DISEASE; BONE DENSITY; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CATARACT; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG MEGADOSE; FIBROSIS; GLAUCOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; INFERTILITY; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PATHOGENESIS; PHOTOSENSITIVE RASH; PREMATURE OVARIAN FAILURE; RASH; RETINA DISEASE; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VIRUS ENCEPHALITIS; WEIGHT GAIN;

EID: 84856463818     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06263.x     Document Type: Article

References (132)

1. Mitka, M. 2011. Treatment for lupus, first in 50 years, offers modest benefits, hope to patients. JAMA 305: 1754-1755.
2. Goodwin, J.S. et al 1986. Mechanism of action of glucocorticosteroids: inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4. J. Clin. Invest. 77: 1244-1250.
3. Newton, R. 2000. Molecular mechanisms of glucocorticoid action: what is important? Thorax 55: 603-613.
4. Barnes, P.J. & M. Karin 1997. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336: 1066-1071.
5. Albert, D.A., N.M. Hadler & M.W. Ropes 1979. Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum. 22: 945-953.
6. Huscher, D. et al 2009. Dose-related patterns of glucocorticoid-induced side effects. Ann. Rheum. Dis. 68: 1119-1124.
7. Ziegler, H.K. & E.R. Unanue 1982. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc. Natl. Acad. Sci. USA 79: 175-178.
8. Kuznik, A. et al 2011. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186: 4794-4804.
9. Group, T.C.H.S. 1991. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. 324: 150-154.
10. James, J.A. et al 2007. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16: 401-409.
11. Petri, M. 2011. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr. Rheumatol. Rep. 13: 77-80.
12. Izmirly, P.M. et al 2010. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann. Rheum. Dis. 69: 1827-1830.
13. Ruiz-Irastorza, G. et al 2010. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69: 20-28.
14. Gourley, M.F. et al 1996. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann. Intern. Med. 125: 549-557.
15. Illei, G.G. et al 2001. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med. 135: 248-257.
16. Wang, C.L., F. Wang & J.J. Bosco 1995. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 4: 11-14.
17. Radis, C.D. et al 1995. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year follow-up study. Arthritis Rheum. 38: 1120-1127.
18. McDermott, E.M. & R.J. Powell 1996. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann. Rheum. Dis. 55: 224-229.
19. Mok, C.C., C.S. Lau & R.W. Wong 1998. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41: 831-837.
20. Ginzler, E.M. et al 2005. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353: 2219-2228.
21. Contreras, G. et al 2004. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350: 971-980.
22. Appel, G.B. et al 2009. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20: 1103-1112.
23. Sinclair, A. et al 2007. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16: 972-980.
24. Isenberg, D. et al 2010. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 49: 128-140.
25. Jorge, S. et al 2008. Mycophenolate mofetil: ten years' experience of a renal transplant unit. Transplant. Proc. 40: 700-704.
26. Sahasranaman, S., D. Howard & S. Roy 2008. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol. 64: 753-767.
27. Grootscholten, C. et al 2006. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis: a randomized controlled trial. Kidney Int. 70: 732-742.
28. Mok, C.C. et al 2009. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus 18: 1091-1095.
29. Skopouli, F.N. et al 1996. Methotrexate in primary Sjogren's syndrome. Clin. Exp. Rheumatol. 14: 555-558.
30. Fortin, P.R. et al 2008. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 59: 1796-1804.
31. Neiman, R.A. & K.H. Fye 1985. Methotrexate induced false photosensitivity reaction. J. Rheumatol. 12: 354-355.
32. Farge, D. et al 2010. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 95: 284-292.
33. Illei, G.G. et al 2011. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann. Rheum. Dis. [epub ahead of print].
34. Arbuckle, M.R. et al 2001. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand. J. Immunol. 54: 211-219.
35. Arbuckle, M.R. et al 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349: 1526-1533.
36. Murawski, N. & M. Pfreundschuh 2010. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol. 11: 1074-1085.
37. Taylor, R.P. & M.A. Lindorfer 2007. Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat. Clin. Pract. Rheumatol. 3: 86-95.
38. Anolik, J.H. et al 2004. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50: 3580-3590.
39. Leandro, M.J. et al 2002. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46: 2673-2677.
40. Ramos-Casals, M. et al 2009. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18: 767-776.
41. Merrill, J.T. et al 2010. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62: 222-233.
42. Furie, R. et al 2009. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. In ACR/ARHP Scientific Meeting. Philadelphia, PA.
43. Merrill, J. et al 2011. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 20: 709-716.
44. Ramos-Casals, M., C. Diaz-Lagares & M.A. Khamashta 2009. Rituximab and lupus: good in real life, bad in controlled trials-comment on the article by Lu et al. Arthritis Rheum. 61: 1281-1282.
45. Lu, T.Y. et al 2009. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 61: 482-487.
46. Clifford, D.B. et al 2011. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68: 1156-1164.
47. Daridon, C. et al 2010. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res. Ther. 12: R204.
48. Mackay, F. & P. Schneider 2009. Cracking the BAFF code. Nat. Rev. Immunol. 9: 491-502.
49. Castigli, E. et al 2005. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat. Genet. 37: 829-834.
50. Zhang, L. et al 2007. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J. Allergy Clin. Immunol. 120: 1178-1185.
51. Cheema, G.S. et al 2001. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44: 1313-1319.
52. Navarra, S.V. et al 2011. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377: 721-731.
53. von Vollenhoven, R.F. et al 2010. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients-BLISS-76 study [Abstract]. Ann. Rheum. Dis. 69(Suppl. 3): 74.
54. Dall'Era, M. et al 2007. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 56: 4142-4150.
55. Pena-Rossi, C. et al 2009. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18: 547-555.
56. Waisman, A. et al 1997. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc. Natl. Acad. Sci. USA 94: 4620-4625.
57. Elmann, A. et al 2007. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum. 56: 2371-2381.
58. Sthoeger, Z.M. et al 2009. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J. Autoimmun. 33: 77-82.
59. Jones, D.S. et al 1995. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J. Med. Chem. 38: 2138-2144.
60. Furie, R.A. et al 2001. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 28: 257-265.
61. Weisman, M.H. et al 1997. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J. Rheumatol. 24: 314-318.
62. Alarcon-Segovia, D. et al 2003. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 48: 442-454.
63. Cardiel, M.H. et al 2008. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 58: 2470-2480.
64. Kyogoku, C. et al 2002. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 46: 1242-1254.
65. Su, K. et al 2004. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J. Immunol. 172: 7192-7199.
66. Kaneko, Y., F. Nimmerjahn & J.V. Ravetch 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
67. Smith, K.G. & M.R. Clatworthy 2010. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10: 328-343.
68. Linker-Israeli, M. et al 1991. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J. Immunol. 147: 117-123.
69. Jeon, J.Y. et al 2010. Interleukin 6 gene polymorphisms are associated with systemic lupus erythematosus in Koreans. J. Rheumatol. 37: 2251-2258.
70. Santos, M.J. et al 2011. Interleukin-6 promoter polymorphism -174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. Clin. Rheumatol. 30: 409-413.
71. Illei, G.G. et al 2010. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62: 542-552.
72. Aringer, M. et al 2004. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50: 3161-3169.
73. Ali, Y. & S. Shah 2002. Infliximab-induced systemic lupus erythematosus. Ann. Intern. Med. 137: 625-626.
74. Favalli, E.G. et al 2002. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11: 753-755.
75. Llorente, L. et al 2000. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43: 1790-1800.
76. Crispin, J.C. et al 2008. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181: 8761-8766.
77. Wong, C.K. et al 2008. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 127: 385-393.
78. Zhang, Z., V.C. Kyttaris & G.C. Tsokos 2009. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 183: 3160-3169.
79. Kang, H.K., M. Liu & S.K. Datta 2007. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J. Immunol. 178: 7849-7858.
80. Hueber, W. et al 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2: 52ra72.
81. Griffiths, C.E. et al 2010. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362: 118-128.
82. Chaussabel, D. et al 2008. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29: 150-164.
83. Preble, O.T. et al 1982. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 216: 429-431.
84. Ytterberg, S.R. & T.J. Schnitzer 1982. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 25: 401-406.
85. Garcia-Romo, G.S. et al 2011. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3: 73ra20.
86. Yao, Y. et al 2009. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60: 1785-1796.
87. Desai-Mehta, A. et al 1996. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 97: 2063-2073.
88. Harigai, M. et al 1999. Responsiveness of peripheral blood B cells to recombinant CD40 ligand in patients with systemic lupus erythematosus. Lupus 8: 227-233.
89. Huang, W. et al 2002. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 46: 1554-1562.
90. Patel, V.L., J. Schwartz & J.B. Bussel 2008. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br. J. Haematol. 141: 545-548.
91. Boumpas, D.T. et al 2003. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48: 719-727.
92. Robles-Carrillo, L. et al 2010. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol. 185: 1577-1583.
93. Kalunian, K.C. et al 2002. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46: 3251-3258.
94. Merrill, J.T. et al 2010. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62: 3077-3087.
95. Larsen, C.P. et al 2010. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 90: 1528-1535.
96. Weber, J. 2009. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother. 58: 823-830.
97. Yang, J.H. et al 2005. Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus. Rheumatology (Oxford) 44: 1245-1254.
98. Nurieva, R.I. et al 2003. Inducible costimulator is essential for collagen-induced arthritis. J. Clin. Invest. 111: 701-706.
99. Hu, Y.L. et al 2009. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J. Immunol. 182: 1421-1428.
100. Solomou, E.E. et al 2001. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 166: 4216-4222.
101. Scheinecker, C., M. Bonelli & J.S. Smolen 2010. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun. 35: 269-275.
102. Enyedy, E.J. et al 2001. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 44: 1114-1121.
103. Krishnan, S. et al 2003. The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J. Immunol. 170: 4189-4195.
104. Deng, G.M. et al 2010. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 62: 2086-2092.
105. Weinblatt, M.E. et al 2010. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363: 1303-1312.
106. Ghoreschi, K. et al 2011. Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550). J. Immunol. 186: 4234-4243.
107. Garber, K. 2011. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat. Biotechnol. 29: 467-468.
108. Kremer, J.M. et al 2009. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum. 60: 1895-1905.
109. Humrich, J.Y. et al 2010. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl. Acad. Sci. USA 107: 204-209.
110. Juang, Y.T. et al 2005. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 115: 996-1005.
111. Ichinose, K. et al 2011. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 63: 523-529.
112. Moroni, G., A. Doria & C. Ponticelli 2009. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol. Dial. Transplant. 24: 15-20.
113. Kyttaris, V.C. et al 2011. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum. 63: 2058-2066.
114. Crispin, J.C. et al 2010. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum. 62: 1431-1437.
115. Li, Y. et al 2007. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J. Immunol. 178: 1938-1947.
116. Biswas, P.S. et al 2010. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 120: 3280-3295.
117. Wang, G. et al 2010. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum. 62: 2064-2072.
118. Karlson, E.W. et al 2007. Effect of glutathione S-transferase polymorphisms and proximity to hazardous waste sites on time to systemic lupus erythematosus diagnosis: results from the Roxbury lupus project. Arthritis Rheum. 56: 244-254.
119. Suwannaroj, S. et al 2001. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 10: 258-265.
120. Tewthanom, K. et al 2010. The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review. J. Clin. Pharm. Ther. 35: 483-485.
121. Gergely, P., Jr. et al 2002. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 46: 175-190.
122. Fernandez, D.R. et al 2009. Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J. Immunol. 182: 2063-2073.
123. Lui, S.L. et al 2008. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 17: 305-313.
124. Fernandez, D. et al 2006. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 2983-2988.
125. Lu, Q. et al 2007. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 179: 6352-6358.
126. Zhao, M. et al 2010. Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus. J. Biomed. Biotechnol. 2010: 931018.
127. Sunahori, K. et al 2011. Promoter hypomethylation results in increased expression of protein phosphatase 2A in T cells from patients with systemic lupus erythematosus. J. Immunol. 186: 4508-4517.
128. Tenbrock, K. et al 2005. The cyclic AMP response element modulator regulates transcription of the TCR zeta-chain. J. Immunol. 175: 5975-5980.
129. Reilly, C.M. et al 2008. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 31: 123-130.
130. Wang, Y. et al 1996. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA 93: 8563-8568.
131. Bao, L. & R.J. Quigg 2007. Complement in lupus nephritis: the good, the bad, and the unknown. Semin. Nephrol. 27: 69-80.
132. Barrat, F.J. et al 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37: 3582-3586.